Many patients using Victoza eventually explore Ozempic for stronger appetite suppression or greater weight loss. Here’s why some switch GLP-1 medications and what doctors consider before changing treatment.
Victoza is widely known as a diabetes medication, but many patients also experience weight loss while using it. Here’s how liraglutide changes appetite, digestion, and metabolic health — plus the risks physicians monitor closely.
Semaglutide may reshape more than appetite—it can influence the brain’s reward system. Here’s what science says about anhedonia and mood changes on GLP-1 drugs.
GLP-1 weight loss drugs are transforming obesity care—but their high cost raises urgent questions about access, insurance coverage, and long-term sustainability.
Semaglutide and tirzepatide are transforming obesity treatment through hormone-based therapy. Here’s how their mechanisms, outcomes, and risks compare.
Mounjaro and Zepbound contain the same drug—tirzepatide—but serve different purposes. Here’s how they compare in weight loss, diabetes control, and cost.
Can diabetes drugs protect the brain? New trials of GLP-1 medications show mixed results in Alzheimer’s disease, revealing both promise and critical limitations.
Ozempic and Wegovy share the same active ingredient, but their clinical roles differ. Here’s how dosing, approvals, and outcomes shape real-world use.
This guide explains how GLP-1 drugs work, their benefits, side effects, and safety considerations for diabetes and weight management in the U.S. and Canada.
Celebrities using GLP-1 weight-loss drugs like Ozempic and Wegovy are bringing attention to “Ozempic Face.” These facial changes are linked to rapid weight loss, not the medication itself, and can often improve over time.